Kenney CT, Marraffini LA.  2023.  Rarely acquired type II-A CRISPR-Cas spacers mediate anti-viral immunity through the targeting of a non-canonical PAM sequence.. Nucleic Acids Res. 51(14):7438-7450.

Chui AJ, Okondo MC, Rao SD, Gai K, Griswold AR, Johnson DC, Ball DP, Taabazuing CY, Orth EL, Vittimberga BA et al..  2019.  N-terminal degradation activates the NLRP1B inflammasome.. Science. 364(6435):82-85.

Callahan SJ, Tepan S, Zhang YM, Lindsay H, Burger A, Campbell NR, Kim IS, Hollmann TJ, Studer L, Mosimann C et al..  2018.  Cancer modeling by Transgene Electroporation in Adult Zebrafish (TEAZ).. Dis Model Mech. 11(9)

Zhang P, Zhao G, Ji L, Yin J, Lu L, Li W, Zhou G, Chaum E, Yue J.  2018.  Knockdown of survivin results in inhibition of epithelial to mesenchymal transition in retinal pigment epithelial cells by attenuating the TGFβ pathway.. Biochem Biophys Res Commun. 498(3):573-578.

Zafra MPaz, Schatoff EM, Katti A, Foronda M, Breinig M, Schweitzer AY, Simon A, Han T, Goswami S, Montgomery E et al..  2018.  Optimized base editors enable efficient editing in cells, organoids and mice.. Nat Biotechnol. 36(9):888-893.

Stopschinski BE, Holmes BB, Miller GM, Manon VA, Vaquer-Alicea J, Prueitt WL, Hsieh-Wilson LC, Diamond MI.  2018.  Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau α-synuclein and β-amyloid aggregates.. J Biol Chem. 293(27):10826-10840.

Pulecio J, Verma N, Mejía-Ramírez E, Huangfu D, Raya A.  2017.  CRISPR/Cas9-Based Engineering of the Epigenome.. Cell Stem Cell. 21(4):431-447.

Verma N, Zhu Z, Huangfu D.  2017.  CRISPR/Cas-Mediated Knockin in Human Pluripotent Stem Cells.. Methods Mol Biol. 1513:119-140.

Perez AR, Pritykin Y, Vidigal JA, Chhangawala S, Zamparo L, Leslie CS, Ventura A.  2017.  GuideScan software for improved single and paired CRISPR guide RNA design.. Nat Biotechnol. 35(4):347-349.

Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS et al..  2017.  HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase.. Sci Transl Med. 9(398)

Hoban MD, Lumaquin D, Kuo CY, Romero Z, Long J, Ho M, Young CS, Mojadidi M, Fitz-Gibbon S, Cooper AR et al..  2016.  CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.. Mol Ther. 24(9):1561-9.

Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KMoore, Gregg A, Noggle S, Tessier-Lavigne M.  2016.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.. Nature. 533(7601):125-9.

Dow LE, Fisher J, O'Rourke KP, Muley A, Kastenhuber ER, Livshits G, Tschaharganeh DF, Socci ND, Lowe SW.  2015.  Inducible in vivo genome editing with CRISPR-Cas9.. Nat Biotechnol. 33(4):390-394.

Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, Fischetti VA, Marraffini LA.  2014.  Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.. Nat Biotechnol. 32(11):1146-50.